











Molecule	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
Zanubrutinib	BTK inhibitor	CLL/SLL				US, EU (CLL), and several ex-EU/US countries
		WM				US, EU, and several ex-EU/US countries
		R/R FL				US, EU, and several ex-EU/US countries
		R/R MZL				US, EU, and several ex-EU/US countries
		TN MCL				
		R/R MCL				US and some ex-US countries
		R/R DLBCL with CD79B				
		Previously treated B-cell malignancies				
Sonrotoclax	BCL2 inhibitor	TN CLL ^a				
		R/R WM				
		R/R CLL				
		R/R MCL				
		TN CLL/SLL [†]				
		R/R MM with t(11;14)				
		AML/MDS				
		B-cell malignancies				

Safety and efficacy have not been established for investigational molecules and/or uses.

Abbreviations: AML, acute myeloid leukemia; BCL2, B-cell lymphoma 2; BTK, Bruton tyrosine kinase; CD79B, cluster of differentiation 79B; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndromes; MM, multiple myeloma; MZL, marginal zone lymphoma; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; TN, treatment naive; WM, Waldenström macroglobulinemia.

^aIn combination with zanubrutinib.

[†]Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

Molecule	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
BGB-16673	BTK CDAC	B-cell malignancies				
		B-cell malignancies [†]				
		R/R MCL and R/R CLL				
BGB-21447	next gen BCL2 inhibitor	B-cell malignancies				
Tislelizumab	PD-1 mAb	R/R cHL				China
Ociperlimab	TIGIT mAb	R/R DLBCL				
Zanubrutinib	BTK inhibitor	Primary membranous nephropathy				
		Lupus nephritis				
BGB-45035	IRAK4 CDAC	Immunology & inflammation				
Blinatumomab ¹	CD3 x CD19 BsAb	Pediatric R/R BP-ALL				

Safety and efficacy have not been established for investigational molecules and/or uses.

Abbreviations: BCL2, B-cell lymphoma 2; BP-ALL, B-cell precursor acute lymphoblastic leukemia; BsAb, bispecific antibody; BTK, Bruton tyrosine kinase; CD3, cluster of differentiation 3; CD19, cluster of differentiation 19; CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; IRAK4, interleukin-1 receptor-associated kinase 4; mAb, monoclonal antibody; MCL, mantle cell lymphoma; PD-1, programmed cell death protein 1; R/R, recurrent/refractory; TIGIT, T-cell immunoreceptor with Ig and ITIM domains.

[†]Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

¹Amgen collaboration; BeiGene has China commercial rights.